While we expect this to negatively impact short-term performance, we continue to believe in the excellent, long-term fundamentals of our company and will continue to manage through these challenges with strategic focus and the winning spirit of our talented global team.”. Collaborating with a global manufacturer of commercial ventilators to source and produce product components, thereby expanding its supply chain capacity, to enable its increased production of transportable ventilators. Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. See All News » Company Profile. All rights reserved. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Press release content from PR Newswire. Availability of latest-generation devices Such as ANGIOGUARD RX Guidewire System, by Cardinal Health & FilterWire EZ by Boston Scientific, is driving the growth of the filter devices segment. Additionally, the company is supporting employees who are trained healthcare providers choosing to volunteer as supplemental staff for hospitals in need of additional nurses, doctors and clinicians. Therefore, if you are accessing this website from one of those countries and you are not a healthcare professional, you need to exit this site immediately, since you would be viewing information that may not be legally allowed under the laws of your country of residence. This includes previous and planned donations of protective personal equipment (PPE) and medical equipment to local hospitals and government agencies. Wall Street brokerages expect Boston Scientific Co. (NYSE:BSX) to report earnings per share of $0.25 for the current quarter, according to Zacks. On November 5, 2019, Jeff Mirviss,... Boston Scientific Corporation (NYSE: BSX) generated sales of $2.707 billion during the third quarter of 2019. The Company has... Boston Scientific Corporation (the "Company") (NYSE: BSX) announced the pricing of a public offering of €900,000,000 aggregate principal amount of its 0.625% notes due 2027, under the Company's... Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the pricing terms of the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate... Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at... Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate... Boston Scientific Corporation (NYSE: BSX) will participate in four conferences, including one industry conference and three investor conferences, this month. The call will begin at 8:00 a.m. EDT, hosted by Mike Mahoney and Dan Brennan, executive vice president and chief financial officer, Boston Scientific. Eight analysts have made estimates for Boston Scientific’s earnings, with estimates ranging from $0.20 to $0.32. Boston Scientific reported earnings per share of $0.39 in the same quarter last year, which […] “Boston Scientific is committed to working alongside its global stakeholders to emerge from this challenging time stronger, together, so we can continue to deliver innovative medical solutions and improve the health of patients around the world,” said Mike Mahoney. ... Boston Scientific (BSC) does not promote or encourage the use of its devices outside their approved labeling. Analysts expect that Boston Scientific Co. (NYSE:BSX) will report earnings per share (EPS) of $0.25 for the current fiscal quarter, Zacks Investment Research reports. Should you disregard this warning notice, Boston Scientific declines any liability as to your access to your access to such information. Several initiatives are underway. View the latest Boston Scientific Corp. (BSX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The joint team intends to design and build prototypes, collect clinical feedback, obtain regulatory approval and distribute a significant quantity of reusable PPE that can be used in place of the combination N95 respirator and face shield. Eight analysts have issued estimates for Boston Scientific’s earnings, with the highest EPS estimate coming in at $0.32 and the lowest estimate coming in at $0.20. To help meet the urgent needs of healthcare providers, Boston Scientific continues to contribute to COVID-19 relief efforts globally through monetary and supply donations, and by providing engineering and manufacturing expertise and resources. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. Explore Educare, our globally recognized education program, Fueling the next generation of life science professionals. Read about latest hot topics, news, and innovations in endoscopy. DISCLAIMER: Please be informed that in some EU countries (Bulgaria, Cyprus, Estonia, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia, Belgium , Netherlands, Slovenia and Spain) medical device advertisement to general public is not permitted. All rights reserved. On Wednesday, December 4, 2019, Susie Lisa, vice president, Investor Relations, and... Boston Scientific Corporation (NYSE: BSX) (the "Company") completed a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027 (the "Notes"). ACCESS is the online magazine for advancing the practice of endoscopy. MARLBOROUGH, Mass., April 2, 2020 /PRNewswire/ -- The COVID-19 pandemic has brought unprecedented challenges upon the global community and the many healthcare providers who are caring for patients. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook. Find the latest Boston Scientific Corporation (BSX) stock quote, history, news and other vital information to help you with your stock trading and investing. The company will issue a news release announcing financial results for the first quarter on Wednesday, April 29, 2020, prior to the conference call. The call will begin at 8:00 a.m. EDT, hosted by Mike Mahoney and Dan Brennan, executive vice president and chief financial officer, Boston Scientific. The machine is intended to work as a one-armed robot to pump an Ambu® bag, replacing the need for manual respiration in emergency settings. *Organic revenue excludes the impact of foreign currency fluctuations and sales from the recent acquisitions of Vertiflex, Inc and BTG plc (BTG), each with no prior year comparable sales. The company will issue a news release announcing financial results for the first quarter on Wednesday, April … Final sales results, other operating metrics and business highlights will be provided on the first quarter earnings call scheduled for April 29, 2020. The company has also strategically decreased discretionary spending and implemented precautionary measures to ensure business continuity in its supply chain and manufacturing facilities, including rotational shifts, segregating buildings and limiting movement across building sites. Many Boston Scientific employees are lending their time and expertise to collaborate with hospitals, universities and industry peers to find new and innovative ways to address the urgent demand for PPE and ventilators. These forward-looking statements include, among other things, statements regarding our business plans and product performance and impact, and the impact of the COVID-19 outbreak on the Company’s results of operations. During this time of concern and disruption, Boston Scientific Corporation (NYSE: BSX) has taken important actions to reduce the spread of the virus in local communities and support global relief efforts, while implementing business continuity plans. Subsequently, the company now expects first quarter 2020 revenue growth on a GAAP basis to be approximately flat to up slightly versus the prior year period, and an organic* revenue decline of approximately two to three percent. The replay will be available beginning approximately one hour following the completion of the event. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. This cautionary statement is applicable to all forward-looking statements contained in this document.
.
Elton John Resale Tickets,
Esso España,
Hanako Yamada Nemesis,
Ubuntu Lantern,
Vitus Womens Bike,
I'm Still Here From Follies,
Australia Universities Ranking,